Man Group’s Beam Therapeutics BEAM Stock Holding History

Man Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.46M	Sell	129,820 -102,174	-44%	-$3.08M	0.01%	1200
2026 Q1	$5.53M	Buy	+231,994	New	+$6.44M	0.01%	1102
2025 Q4	–	Sell	-71,720	Closed	-$1.74M	–	2254
2025 Q3	$1.74M	Buy	+71,720	New	+$1.43M	﹤0.01%	1471
2023 Q3	–	Sell	-65,944	Closed	-$1.77M	–	1632
2023 Q2	$2.11M	Buy	+65,944	New	+$2.14M	0.01%	1179
2023 Q1	–	Hold	0	–	–	–	1680
2022 Q2	–	Sell	-11,698	Closed	-$465K	–	919
2022 Q1	$670K	Buy	+11,698	New	+$767K	﹤0.01%	1494
2021 Q2	–	Sell	-6,858	Closed	-$549K	–	1957
2021 Q1	$549K	Buy	6,858 +4,153	+154%	+$395K	﹤0.01%	1453
2020 Q4	$220K	Buy	+2,705	New	+$133K	﹤0.01%	1717

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Man Group's BEAM Position: Q2 2026 in Review

Man Group reduced its Beam Therapeutics (BEAM) stake by 44% in Q2 2026, selling an estimated $3.08M and leaving 129,820 shares worth $4.46M. The position accounts for 0.01% of the portfolio, ranked #1200.

Man Group first reported a position in BEAM in Q4 2020 and has held it in 7 quarters since. The position peaked at $5.53M in Q1 2026. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Man Group held 129,820 shares of Beam Therapeutics worth $4.46M as of Q2 2026.
Man Group sold 102,174 Beam Therapeutics shares in Q2 2026, an estimated $3.08M.
Beam Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #1200 holding.
Man Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 7 quarters since.
Man Group's Beam Therapeutics position peaked at $5.53M in Q1 2026.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.